Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean
- PMID: 25444798
- DOI: 10.1016/j.vaccine.2014.10.070
Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean
Abstract
As part of the vaccination activities against influenza A[H1N1]pdm vaccine in 2009-2010, countries in Latin American and the Caribbean (LAC) implemented surveillance of events supposedly attributable to vaccines and immunization (ESAVI). We describe the serious ESAVI reported in LAC in order to further document the safety profile of this vaccine and highlight lessons learned. We reviewed data from serious H1N1 ESAVI cases from LAC countries reported to the Pan American Health Organization/World Health Organization. We estimated serious ESAVI rates by age and target group, as well as by clinical diagnosis, and completed descriptive analyses of final outcomes and classifications given in country. A total of 1000 serious ESAVI were reported by 18 of the 29 LAC countries that vaccinated against A[H1N1]pdm. The overall reporting rate in LAC was 6.91 serious ESAVI per million doses, with country reporting rates ranging from 0.77 to 64.68 per million doses. Rates were higher among pregnant women (16.25 per million doses) when compared to health care workers (13.54 per million doses) and individuals with chronic disease (4.03 per million doses). The top three most frequent diagnoses were febrile seizures (12.0%), Guillain-Barré Syndrome (10.5%) and acute pneumonia (8.0%). Almost half (49.1%) of the serious ESAVI were reported among children aged <18 years of age; within this group, the highest proportion of cases was reported among those aged <2 years (53.1%). Of all serious ESAVI reported, 37.8% were classified as coincidental, 35.3% as related to vaccine components, 26.4% as non-conclusive and 0.5% as a programmatic error. This regional overview of A[H1N1]pdm vaccine safety data in LAC estimated the rate of serious ESAVI at lower levels than other studies. However, the ESAVI diagnosis distribution is comparable to the published literature. Lessons learned can be applied in the response to future pandemics.
Keywords: Events supposedly attributable to vaccines and immunization; Febrile seizures; Guillain-Barré; H1N1; Pandemic influenza; Vaccine safety.
Copyright © 2014. Published by Elsevier Ltd.
Similar articles
-
Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.Lancet. 2013 Apr 27;381(9876):1461-8. doi: 10.1016/S0140-6736(12)62189-8. Epub 2013 Mar 13. Lancet. 2013. PMID: 23498095
-
Guillain-Barré syndrome in children aged <15 years in Latin America and the Caribbean: baseline rates in the context of the influenza A (H1N1) pandemic.J Infect Dis. 2010 Mar;201(5):746-50. doi: 10.1086/650530. J Infect Dis. 2010. PMID: 20102270
-
Pandemic influenza vaccination: lessons learned from Latin America and the Caribbean.Vaccine. 2012 Jan 20;30(5):916-21. doi: 10.1016/j.vaccine.2011.11.092. Epub 2011 Dec 11. Vaccine. 2012. PMID: 22155136
-
Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review.Vaccine. 2012 Nov 19;30(49):7123-9. doi: 10.1016/j.vaccine.2012.09.032. Epub 2012 Sep 26. Vaccine. 2012. PMID: 23022149 Review.
-
Safety of pandemic H1N1 vaccines in children and adolescents.Vaccine. 2011 Oct 6;29(43):7559-71. doi: 10.1016/j.vaccine.2011.08.016. Epub 2011 Aug 5. Vaccine. 2011. PMID: 21821086 Review.
Cited by
-
Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives.Allergy. 2021 Jun;76(6):1640-1660. doi: 10.1111/all.14840. Epub 2021 Jun 4. Allergy. 2021. PMID: 33811364 Free PMC article. Review.
-
Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years.Vaccine. 2016 Jun 17;34(29):3342-9. doi: 10.1016/j.vaccine.2016.05.018. Epub 2016 May 16. Vaccine. 2016. PMID: 27195758 Free PMC article. Review.
-
Relief After COVID-19 Vaccination: A Doubtful or Evident Outcome?Front Med (Lausanne). 2022 Jan 10;8:800040. doi: 10.3389/fmed.2021.800040. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35083249 Free PMC article.
-
Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines.Hum Vaccin Immunother. 2025 Dec;21(1):2463191. doi: 10.1080/21645515.2025.2463191. Epub 2025 Feb 11. Hum Vaccin Immunother. 2025. PMID: 39932481 Free PMC article.
-
Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis.Front Immunol. 2022 Feb 3;13:782198. doi: 10.3389/fimmu.2022.782198. eCollection 2022. Front Immunol. 2022. PMID: 35185881 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials